Compounded Semaglutide Explained: What Adults Should Know

A responsible read on this review starts with mechanism, side effects, access, and monitoring rather than promises. That frame keeps the discussion useful for patients without pretending the evidence is stronger than it is.

Last October I sat across from a patient, a 52-year-old school counselor named Diane, during a telehealth follow-up. She’d been on compounded semaglutide for ten weeks. She was tolerating the 1.0 mg step fine, her nausea had mostly resolved around week six, and she’d lost about 18 pounds. But her question wasn’t about weight. “My sister’s endocrinologist told her compounded semaglutide is basically counterfeit,” she said. “Should I be worried?”

That question, or some version of it, comes up constantly. And the honest answer is more boring than either camp wants to admit. Compounded semaglutide is the same active pharmaceutical ingredient found in Ozempic and Wegovy, prepared by a state-licensed or 503A compounding pharmacy for an individual patient under a clinician’s prescription. It is not FDA-approved as a finished product. It is also not counterfeit. Those two facts can coexist, and understanding the space between them is most of what a patient actually needs.

The Molecule and Where It Comes From

Semaglutide is a GLP-1 receptor agonist. Novo Nordisk developed it and brought it to market as Ozempic in 2017 (for type 2 diabetes) and Wegovy in 2021 (for chronic weight management). GLP-1 is an incretin hormone your intestinal L-cells release after you eat. It stimulates insulin secretion in a glucose-dependent way, suppresses glucagon, slows gastric emptying, and acts on hypothalamic centers that regulate appetite. The combination produces both the metabolic improvements and the weight effects seen in trial data.

The compounded pathway operates under section 503A of the Federal Food, Drug, and Cosmetic Act, plus parallel state pharmacy regulations. Compounding pharmacies have been filling prescriptions this way for decades across many drug classes. It’s not new, and it’s not unique to GLP-1 therapy. What is relatively new is the sheer volume of demand, which has stress-tested a system that was designed for lower-volume, patient-specific preparations.

What the Trials Actually Showed

The STEP trial program is the clinical backbone. STEP-1 randomized 1,961 adults with overweight or obesity, without diabetes, to weekly semaglutide 2.4 mg or placebo for 68 weeks alongside lifestyle intervention. The semaglutide group lost approximately 14.9% of body weight versus 2.4% in the placebo group (Wilding et al., New England Journal of Medicine, 2021). Individual responders ranged widely, which matters more to actual patients than the mean. STEP-3 layered in intensive behavioral therapy and saw a directionally similar, somewhat larger effect. STEP-5 extended follow-up to 104 weeks and showed sustained weight reduction in the active arm.

For diabetes, the SUSTAIN program established glycemic and cardiovascular benefits at the lower dose range (0.5 mg and 1.0 mg weekly, with 2.0 mg added in SUSTAIN FORTE). SUSTAIN-6, the cardiovascular outcome trial, reported a reduction in the composite of major adverse cardiovascular events in a high-risk diabetes population (Marso SP et al.).

Here’s the important caveat: all of that evidence was generated using the brand-name finished product manufactured by Novo Nordisk. Compounded preparations contain the same active ingredient, but they have not been studied as finished products in registrational trials. The pharmacological effect is expected to track, but “expected to track” and “proven in a Phase III trial” are different statements. A careful program acknowledges the difference rather than pretending it doesn’t exist.

Titration, Dosing, and the Stuff Nobody Wants to Talk About

The standard titration from the Wegovy label is a five-step escalation: 0.25 mg weekly for four weeks, 0.5 mg for four, 1.0 mg for four, 1.7 mg for four, then 2.4 mg as the maintenance dose. Full escalation takes about sixteen to seventeen weeks.

Most compounded programs follow the same milligram increments. Where things diverge is in how the pharmacy formats the preparation. Concentration and syringe volume vary. A patient drawing 0.25 mg from one pharmacy’s vial might draw a different volume than from another’s. The dose in milligrams is what matters clinically, not the volume. If you’re switching programs or pharmacies, confirm the milligram dose at each step. This is one of those boring details that prevents real problems.

The schedule is also flexible. A patient struggling with nausea at 0.5 mg can stay there for an extra four weeks. A patient doing well clinically at 1.7 mg can elect to stay there instead of pushing to 2.4 mg. The decision should be clinical, not procedural. I’ve had patients plateau beautifully at 1.0 mg and never need a higher dose. Others need the full 2.4 mg before the appetite signal meaningfully shifts. Both outcomes are normal.

Storage: refrigerate at 36 to 46 degrees Fahrenheit, with limited room-temperature time acceptable for transport. Injection-site rotation between abdomen, thigh, and upper arm reduces local irritation. These are small things that meaningfully affect the daily experience.

Side Effects: What to Expect and What to Watch For

Gastrointestinal symptoms dominate. Nausea, diarrhea, constipation, vomiting, abdominal discomfort. These are reported across the STEP and SUSTAIN programs and show up consistently in real-world cohorts too. Most are mild to moderate, peak during the first eight to twelve weeks, and resolve with continued therapy or a temporary dose hold.

The less common events deserve specific attention. Gallbladder events occur more frequently in patients with rapid weight loss (this is true of rapid weight loss from any cause, not just semaglutide). Acute pancreatitis is rare but requires prompt evaluation if you develop persistent severe abdominal pain radiating to the back. There’s a theoretical signal for thyroid C-cell tumors from rodent data that has not been replicated in humans, but it’s taken seriously enough that both the Wegovy and Ozempic labels carry a boxed warning. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not be on this medication, period.

Hypoglycemia on semaglutide monotherapy in non-diabetic patients is uncommon because the insulin stimulation is glucose-dependent. The risk climbs when semaglutide is paired with insulin or sulfonylureas, which is a diabetes-specific concern that requires dose adjustment of those other agents.

The thing that separates a good program from a mediocre one is how clearly they walk you through these scenarios before you start, not after you’re panicking at 2 a.m. with nausea.

What Compounded Semaglutide Costs (and Why)

Brand-name Wegovy and Ozempic list north of $1,300 per month in the U.S. Cash-pay rates at most retail pharmacies run $1,000 to $1,400. Insurance coverage for weight-management indications is inconsistent, and “inconsistent” is generous. Some plans cover it, many don’t, and the prior authorization process can feel like a part-time job.

Compounded semaglutide through compliant telehealth programs costs substantially less. HealthRX, for instance, prices its program at $179.99 to $279.99 per month depending on dose, available in 44 states, and operated under LegitScript certification.

The pricing gap is structural, not suspicious. Brand-name products carry the cost of manufacturing scale-up, FDA regulatory submissions, post-marketing surveillance, and the commercial margin that funds Novo Nordisk’s next pipeline molecule. Compounded preparations are produced at a different scale through a different regulatory pathway with a fundamentally different cost structure. It’s like comparing the price of a custom-built cabinet to one from a national furniture chain. Different supply chain, different overhead, same wood.

If you’re using an HSA or FSA, confirm the program’s invoicing format before enrolling. Some programs generate receipts that process cleanly through those accounts; others don’t.

The Brand-Name vs. Compounded Comparison, Honestly

This is where I think most articles get it wrong, because they either collapse the distinction entirely (“it’s the same thing!”) or inflate it into something it isn’t (“compounded is dangerous!”).

Three practical differences matter:

First, the clinical evidence base. STEP and SUSTAIN trials were conducted with brand-name finished products. That data informs expectations for the compounded version but does not directly extend to it.

Second, manufacturing oversight. Compounded pharmacies are regulated by state boards of pharmacy. 503B outsourcing facilities are regulated by the FDA under a different framework than finished-product manufacturers. The oversight model is real but different.

Third, adverse-event surveillance. The post-marketing safety net is less complete for compounded preparations than for branded products with formal pharmacovigilance systems.

None of these points mean compounded semaglutide is unsafe by default. They mean the frameworks are different, and a patient deserves to know that rather than have the differences buried in marketing copy. Patients comparing pathways benefit from talking it through with a clinician who has no financial incentive to push them toward either option. For those who want background reading that connects the mechanism to the practical food and dosing questions that come up in the first few months, this review is structured around the questions that arise in a real intake and can make a clinical conversation more productive.

When to Contact Your Clinician (Not Google)

Persistent severe abdominal pain, especially with radiation to the back or fever: call. Inability to keep down fluids for more than 24 hours, signs of dehydration, persistent vomiting: call. New right upper quadrant pain after meals or jaundice (gallbladder territory): get evaluated. Reflux that doesn’t respond to meal-timing adjustments: raise it at your next check-in. New or worsening mood changes, including depressive symptoms: surface this, don’t sit on it.

Pregnancy, planned pregnancy, or breastfeeding: have the conversation before your next dose. Patients on insulin, sulfonylureas, warfarin, or other narrow-therapeutic-window medications should flag any new symptoms promptly, because slowed gastric emptying can alter absorption timing of concurrent drugs.

Frequently Asked Questions

Is compounded semaglutide the same drug as Ozempic and Wegovy? The active ingredient, semaglutide, is the same. The finished product, regulatory category, and manufacturing pathway are different. Ozempic and Wegovy are FDA-approved finished products made by Novo Nordisk. Compounded semaglutide is prepared by a licensed compounding pharmacy for an individual patient under a clinician’s prescription and is not FDA-approved as a finished product.

How long does treatment typically last? STEP-1 captures 68 weeks, STEP-5 extends to 104 weeks, and clinical experience now runs well beyond two years. Duration is individualized based on the patient’s goals, response, and tolerability.

Is the weight loss sustained after stopping? STEP-4 showed significant regain in the group switched to placebo after a lead-in period, suggesting the metabolic effect depends on continued therapy for many patients. Long-term outcomes after discontinuation hinge on the lifestyle changes consolidated during treatment.

Do I need labs to start? A responsible program will document baseline labs, typically a metabolic panel, lipid panel, A1c, and in some patients a thyroid panel. The specific set depends on your clinical picture.

Is semaglutide right for everyone? No. Pregnancy, breastfeeding, personal or family history of medullary thyroid carcinoma or MEN2, and certain GI conditions are contraindications or relative contraindications. These should be surfaced at intake before therapy begins.

Can I switch between compounded and brand-name semaglutide? Yes, with coordination. Confirm the milligram dose you’re on and ensure continuity of the titration schedule. Your clinician should manage the transition.

What if I miss a dose? If fewer than five days have passed since the missed dose, take it as soon as possible. If five or more days have passed, skip that dose and take the next one on schedule. Don’t double up.

References: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384:989-1002 (STEP-1). Wadden TA et al. STEP-3. Rubino DM et al. STEP-4. Garvey WT et al. STEP-5. Davies M et al. STEP-2. SUSTAIN-6 (Marso SP et al.). Wegovy and Ozempic prescribing information (Novo Nordisk).

Important Notice

Not FDA-approved. Compounded semaglutide is prepared by licensed compounding pharmacies for individual patients based on a prescriber’s clinical judgment. This article is educational and does not constitute medical advice. Individual results vary.